标题：Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: characterization and evaluation
作者：Liu, Xin; Zhang, Zhihua; Jiang, Yuqi; Hu, Yue; Wang, Zhonglan; Liu, Junli; Feng, Ruihua; Zhang, Jie; Huang, Guihua
作者机构：[Liu, Xin; Zhang, Zhihua; Jiang, Yuqi; Hu, Yue; Wang, Zhonglan; Liu, Junli; Feng, Ruihua; Zhang, Jie; Huang, Guihua] Shandong Univ, Sch Pharmaceut Sci 更多
通讯作者地址：[Huang, GH]Shandong Univ, Sch Pharmaceut Sci, 44 Wenhua Xi Rd, Jinan, Shandong, Peoples R China.
关键词：Biodistribution; intravenous delivery; nanostructured lipid carrier;; PEGylated; pharmacokinetic; Tamibarotene
摘要：Tamibarotene (Am80), a poorly water-soluble drug for the treatment of acute promyelocytic leukemia (APL), loaded nanostructured lipid carrier (Am80-NLC) was developed and characterized previously. The purpose of the present work was to develop PEGylated nanostructured lipid carrier (PEG-NLC) for intravenous delivery of Am80, with the aim to further extend the circulation in blood and decrease the adverse events. Am80-loaded PEG-NLC (Am80-PEG-NLC) modified with PEG-40 stearate (PEG40-SA, molecular weight 2000 Da) was formulated by the method of melt-emulsification and low temperature-solidification technique. Am80-NLC was developed as well as control. Based on the optimized results of single-factor screening experiment, the average drug entrapment efficiency, the mean particle size, and zeta potential of Am80-NLC and Am80-PEG-NLC were found to be 89.8-94.3%, 178.9-201.6 nm, and -37.74 to -20.1 mV, respectively. In vitro drug release of Am80-NLC and Am80-PEG-NLC possessed a sustained release characteristic and their release behavior was in accordance with the Ritger-Peppas equation. In vivo, after intravenous (i.v.) injection to rats, the mean residence time (MRT) of Am80-PEG-NLC group was significantly prolonged and the AUC value was improved as well compared with the Am80-NLC group. Furthermore, the biodistribution in mice showed that Am80-PEG-NLC preferentially decreased the accumulation of Am80 in kidney and increased the drug concentration in brain after i.v. injection. In conclusion, Am80-PEG-NLC may be a potential delivery system for Am80 in the treatment of APL.